Atomo Diagnostics (ASX:AT1) hits back at market enquiry
Following recent trading activity, Atomo Diagnostics (AT1) has hit back at a…
Atomo Diagnostics Limited (ASX:AT1)
24.5¢
-0.01 (-3.92%)
MCAP $144.9M
Last trade
16.10pm 19/01/2022
20mins delayed
Latest Announcements
30/12/2021 Price SensitivePSAT1Atomo Diagnostics Limited
5,973
MCap
10/12/2021AT1Atomo Diagnostics Limited
356
MCap
09/12/2021AT1Atomo Diagnostics Limited
5,737
MCap
26/11/2021AT1Atomo Diagnostics Limited
2,182
MCap
25/11/2021AT1Atomo Diagnostics Limited
1,275
MCap
10/11/2021AT1Atomo Diagnostics Limited
2,391
MCap
08/11/2021AT1Atomo Diagnostics Limited
859
MCap
08/11/2021AT1Atomo Diagnostics Limited
Company Overview
Atomo Diagnostics Ltd is an Australia-based medical device company. The Company is engaged in the development and sale of medical devices. Its AtomoRapid is offering rapid diagnostic test (RDT) platform, which provides devices to the global diagnostic market. Its RDT device platforms include Galileo, Pascal, Losev, Newton, Franklin and Elion. It also offers blood-based rapid diagnostic test (RDT) for screening for human immunodeficiency virus (HIV). Its RDT platform includes various features, such as integrated lancelet, blood collection, buffer delivery and digital display. It is also engaged in sales of Atomo branded COVID-19 rapid antibody and antigen tests in Australia.
